Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 25;8(1):67.
doi: 10.1186/s13550-018-0415-3.

[18F]Fluciclovine PET discrimination between high- and low-grade gliomas

Ephraim E Parent  1 , Marc Benayoun  2 , Ijeoma Ibeanu  3 , Jeffrey J Olson  4 , Constantinos G Hadjipanayis  5 , Daniel J Brat  6 , Vikram Adhikarla  7 , Jonathon Nye  1 , David M Schuster  1 , Mark M Goodman  8
Affiliations

[18F]Fluciclovine PET discrimination between high- and low-grade gliomas

Ephraim E Parent et al. EJNMMI Res. .

Abstract

Background: The ability to accurately and non-invasively distinguish high-grade glioma from low-grade glioma remains a challenge despite advances in molecular and magnetic resonance imaging. We investigated the ability of fluciclovine (18F) PET as a means to identify and distinguish these lesions in patients with known gliomas and to correlate uptake with Ki-67.

Results: Sixteen patients with a total of 18 newly diagnosed low-grade gliomas (n = 6) and high grade gliomas (n = 12) underwent fluciclovine PET imaging after histopathologic assessment. Fluciclovine PET analysis comprised tumor SUVmax and SUVmean, as well as metabolic tumor thresholds (1.3*, 1.6*, 1.9*) to normal brain background (TBmax, and TBmean). Comparison was additionally made to the proliferative status of the tumor as indicated by Ki-67 values. Fluciclovine uptake greater than normal brain parenchyma was found in all lesions studied. Time activity curves demonstrated statistically apparent flattening of the curves for both high-grade gliomas and low-grade gliomas starting 30 min after injection, suggesting an influx/efflux equilibrium. The best semiquantitative metric in discriminating HGG from LGG was obtained utilizing a metabolic 1 tumor threshold of 1.3* contralateral normal brain parenchyma uptake to create a tumor: background (TBmean1.3) cutoff of 2.15 with an overall sensitivity of 97.5% and specificity of 95.5%. Additionally, using a SUVmax > 4.3 cutoff gave a sensitivity of 90.9% and specificity of 97.5%. Tumor SUVmean and tumor SUVmax as a ratio to mean normal contralateral brain were both found to be less relevant predictors of tumor grade. Both SUVmax (R = 0.71, p = 0.0227) and TBmean (TBmean1.3: R = 0.81, p = 0.00081) had a high correlation with the tumor proliferative index Ki-67.

Conclusions: Fluciclovine PET produces high-contrast images between both low-grade and high grade gliomas and normal brain by visual and semiquantitative analysis. Fluciclovine PET appears to discriminate between low-grade glioma and high-grade glioma, but must be validated with a larger sample size.

Keywords: 18F-fluciclovine; Amino acid; Glioma; PET.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The recruitment protocol was approved by the Institutional Review Board (IRB) and complied with the Health Insurance Portability and Accountability Act (HIPPA). Informed consent was obtained from all individual participants included in the study.

Consent for publication

Informed consent was obtained from all individual participants included in the study.

Competing interests

The authors have participated in sponsored research involving 18F-fluciclovine, among other radiotracers. Emory University and Dr. Mark Goodman are eligible to receive royalties for 18F-fluciclovine. The other authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Fluciclovine PET at 30 min post-injection of oligodendroglioma with regions overlaid on MRI. Green sphere is the area of normal brain fluciclovine uptake. Magenta area is the metabolic tumor uptake defined as 1.3* contralateral normal brain uptake (TBmean1.3)
Fig. 2
Fig. 2
Fluciclovine PET at 30 min post-injection of glioblastoma fused with regions overlaid on MRI. Green sphere is the area of normal brain fluciclovine uptake. Magenta area is the metabolic tumor uptake defined as 1.3* contralateral normal brain uptake (TBmean1.3)
Fig. 3
Fig. 3
Time activity curves of HGG (red) and LGG SUVmax (blue) show equilibrium kinetics starting 30 min post-injection. Statistically significant differences are noted between HGG and LGG, normal brain parenchyma SUVmean (green), and venous blood pool SUVmean (purple). Each lesion was compared to the contralateral normal
Fig. 4
Fig. 4
Time activity curves using TBmean for HGG (red) and LGG (blue) with a threshold of 1.3 × SUVmean normal brain parenchyma, b 1.6 × SUVmean normal brain parenchyma, c 1.9 × SUVmean normal brain parenchyma
Fig. 5
Fig. 5
Scatter plot of individual lesion TBmean_1.3 of WHO II, III, and IV tumors at 40 min post-injection
Fig. 6
Fig. 6
Lesion by lesion correlation between fluciclovine TBmean_1.3 and Ki-67
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi: 10.3322/caac.21387. - DOI - PubMed
    1. Cheng JX, Zhang X, Liu BL. Health-related quality of life in patients with high-grade glioma. Neuro-Oncology. 2009;11:41–50. doi: 10.1215/15228517-2008-050. - DOI - PMC - PubMed
    1. Scott JN, Brasher PMA, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947–949. doi: 10.1212/WNL.59.6.947. - DOI - PubMed
    1. Approvals SODDa. U.S. Food & Drug Administration website. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed 30 May 2017.
    1. Sasajima T, Ono T, Shimada N, Doi Y, Oka S, Kanagawa M, et al. Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas. Nucl Med Biol. 2013;40:808–15. 10.1016/j.nucmedbio.2013.04.007. - PubMed